A Practical Utility and Benefit of Pharmacogenetic-based Antidepressant Treatment Strategy for Major Depressive Disorder Patients with Difficult-to-treat

키워드

참고문헌 (25)

1. Changsu Han, "A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial", Clinical Psychopharmacology and Neuroscience, 16(4), pp.469~480 (2018), 대한정신약물학회[DOI]
2. Peterson JF, "Attitudes of clinicians following large-scale pharmacogenomics implementation", Pharmacogenomics J, 16, pp.393~398 (2016)
3. Salm M, "Use of genetic tests among neurologists and psychiatrists : knowledge, attitudes, behaviors, and needs for training", J Genet Couns, 23, pp.156~163 (2014)
4. Pérez V, "Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder : results of a randomized, double-blind clinical trial", BMC Psychiatry, 17, pp.250~ (2017)
5. Espadaler J, "Pharmacogenetic testing for the guidance of psychiatric treatment : a multicenter retrospective analysis", CNS Spectr, 22, pp.315~324 (2017)
6. Bradley P, "Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety : a randomized clinical trial demonstrating clinical utility", J Psychiatr Res, 96, pp.100~107 (2018)
7. Hall-Flavin DK, "Using a pharmacogenomic algorithm to guide the treatment of depression", Transl Psychiatry, 2, pp.e172~ (2012)
8. Winner JG, "A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder", Discov Med, 16, pp.219~227 (2013)
9. Bousman CA, "Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder : a 10-week open-label study", Pharmacogenet Genomics, 27, pp.1~6 (2017)
10. Ajeet B. Singh, "Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report", Clinical Psychopharmacology and Neuroscience, 13(2), pp.150~156 (2015), 대한정신약물학회
11. Hall-Flavin DK, "Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting", Pharmacogenet Genomics, 23, pp.535~548 (2013)
12. Brennan FX, "A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders", Prim Care Companion CNS Disord, 17, pp.e1~ (2015)
13. Rosenblat JD, "The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder : a meta-analysis", J Affect Disord, 241, pp.484~491 (2018)
14. Fabbri C, "Pharmacogenetic tests to guide drug treatment in depression : comparison of the available testing kits and clinical trials", Prog Neuropsychopharmacol Biol Psychiatry, 86, pp.36~44 (2018)
15. Fabbri C, "Progress and prospects in pharmacogenetics of antidepressant drugs", Expert Opin Drug Metab Toxicol, 12, pp.1157~1168 (2016)
16. Nassan M, "Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants : a template for psychiatric precision medicine", Mayo Clin Proc, 91, pp.897~907 (2016)
17. de Leon J, "Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19", Psychosomatics, 47, pp.75~85 (2006)
18. Kennedy SH, "Clinical guidelines for the treatment of depressive disorders. IV. medications and other biological treatments", Can J Psychiatry, 46(Suppl 1), pp.38S~58S (2001)
19. Anderson IM, "Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2000British Association for Psychopharmacology guidelines", J Psychopharmacol, 22, pp.343~396 (2008)
20. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)
21. Patkar AA, "Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder", CNS Drugs, 27(Suppl 1), pp.S29~S37 (2013)
22. Wang SM, "Criticisms of drugs in early development for the treatment of depression: what can be improved?", Expert Opin Investig Drugs, 24, pp.445~453 (2015)
23. Hee Ryung Wang, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 15(3), pp.199~209 (2017), 대한정신약물학회[DOI]
24. Alessandro Serretti, "The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants", Clinical Psychopharmacology and Neuroscience, 16(1), pp.1~6 (2018), 대한정신약물학회[DOI]
25. Changsu Han, "The Potential Utility of Aripiprazole Augmentation for Major Depressive Disorder with Mixed Features Specifier: A Retrospective Study", Clinical Psychopharmacology and Neuroscience, 17(4), pp.495~502 (2019), 대한정신약물학회[DOI]

관련 논문AI추천